All In Biotech

Drug Trial Radar · NCT04181723

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Nov 6, 2019

Primary completion

Oct 28, 2021

Study completion Oct 28, 2021

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 5 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome

Conditions

  • Rett Syndrome

Interventions

  • TrofinetideDrug

    Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

  • PlaceboOther

    Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12Time frame: Baseline and Week 12
  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12Time frame: 12 Weeks Treatment Duration

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Translational Gemomics Research Institute (TGen)

    Phoenix, Arizona

  • University of California, San Diego

    La Jolla, California

  • UC Davis MIND Institute

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children Medical Services

    Tampa, Florida

  • Emory Genetics Clinical Trial Center

    Atlanta, Georgia

  • Rush University Children's Hospital

    Chicago, Illinois

  • Kennedy Krieger Institute - Clinical Trials Unit

    Baltimore, Maryland

  • Boston Children's Hospital Harvard Medical School

    Boston, Massachusetts

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Montefiore Medical Center, Children's Hospital at Montefiore

    The Bronx, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Greenwood Genetic Center

    Greenwood, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Children's Hospital

    Houston, Texas

  • Seattle Children's

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.